Reactions Weekly

, Volume 1635, Issue 1, pp 9–9 | Cite as

Erlotinib reduces AE rate and healthcare costs versus afatinib

Clinical study


  1. Isla D, et al. Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer. ClinicoEconomics and Outcomes Research 2017: 31-38, No. 9, 30 Dec 2016. Available from: URL: CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Personalised recommendations